Kawai M, et al. - Researchers investigated the prognostic value of systemic immune-inflammatory markers after neoadjuvant therapy followed by pancreatectomy to predict survival in patients with borderline resectable pancreatic cancer via retrospectively reviewing 67 borderline resectable pancreatic cancer patients receiving neoadjuvant therapy and 58 borderline resectable pancreatic cancer patients undergoing upfront surgery between 2010 and 2016. In multivariate analysis, following predictors of poor prognosis were identified: post neoadjuvant lymphocyte-to-monocyte ratio <3.0, T4, lymph node status, and no completion of adjuvant therapy. Outcomes thus suggest that lymphocyte-to-monocyte ratios play a potential role in the stratification of treatment strategy in borderline resectable pancreatic cancer patients.